United States · Health Care · USD (Thousands) · Annual
Key financials
USD|Thousands
ROE
-66.33%
2025 (actual)
ROA
-54.57%
2025 (actual)
Gross Margin
100%
2025 (actual)
Net Margin
-
Total Assets
$30,160.00K
2025 (actual)
Net Income
-$26,483.00K
2025 (actual)
Valuation
-
Stock Price
-
Historical & projected performance
USD|Thousands
Reported figures and Equlion model projections for the next 5 years.
ROE
+101.5 pt
Company
Sector average
ROA
-416.1 pt
Company
Gross Margin
+0 pt
Company
Sector average
Total Assets
-66.4%
Company
Sector average (own scale)
Net Income
-74.7%
Company
Detailed data
USD|Thousands
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for VYNE Therapeutics Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.